AstraZeneca plc isn’t the only pharma star that could make you rich

AstraZeneca plc (LON: AZN) isn’t the only pharma giant that could make you rich. Here Royston Wild looks at another drugs star with brilliant earnings potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I have always been a fan of medicines mammoth AstraZeneca (LSE: AZN), and I’m not ashamed to admit it.

Share price trouble is part and parcel of investing in pharmaceuticals and the Cambridge company has been no stranger to this in recent months. It took a dive in July after trialling showed its Imfinzi drug had failed to meet its endpoints, in fact revealing that it was no better at stemming lung cancer growth than traditional chemotherapy.

As if this wasn’t problem enough, the ongoing battle with patent losses was underlined by news that revenues in the US continue to be hit heavily by exclusivity losses on its Crestor and Seroquel XR treatments. This caused global turnover at its Product Sales division to tank 11% in January-June to $9.78bn.

Newsflow has been more promising since then, however, with it announcing earlier this month that its Phase III PACIFIC trial showed that Imfinzi had illustrated an improvement in progression-free survival in patients by more than 11 months. The oncology treatment is still seen by many as a terrific revenues spinner in future years, but this is just one potential star in the company’s bubbling pipeline.

A star for patient investors

Development setbacks in the pharmaceuticals industry arguably make the likes of AstraZeneca poor choices for those with a low risk tolerance, with patchy R&D results often leading to a fortune in lost revenues and extra lab costs.

Having said that, the revenues opportunities created by rising healthcare investment across the globe are vast, and with AstraZeneca zoning in on fast-growth areas like respiratory and oncology treatments, it is putting itself in the frame for exceptional profits growth ahead.

The City expects the company to endure some earnings woe in the near term with an 11% bottom-line decline currently predicted for 2017. But the East Anglian firm is expected to get firing again from next year, a modest 1% rise being predicted at the moment.

While far from spectacular, current figures leave the company trading on a forward P/E ratio of 17.2 times, very decent value in my opinion given the potential for explosive earnings growth. And with AstraZeneca also sporting giant dividend yields of 4.3% and 4.4% for this year and next, I reckon the firm is a great buy right now.

On the right track

Immupharma (LSE: IMM) is another drugs developer I believe offers plenty of investment opportunity.

The company’s share price rose 4% on Wednesday after the release of an encouraging market update. It advised: “The first half of 2017 saw the continued progression of our lead program Lupuzor, for the treatment of lupus, through significant milestones in its pivotal Phase III trial.” All patients had passed through the six-month stage, while just over a quarter had completed the full 12 months of the study.

Accordingly Immupharma announced that it was preparing the relevant regulatory papers for the US Food and Drug Administration and the European Medicines Agency. It hopes to have Phase III testing on Lupuzor completed by quarter one of 2018.

City analysts are forecasting a positive outcome and they expect Immupharma to finally break into the black in 2018 with earnings of 9p per share. With the company subsequently dealing on a corresponding P/E ratio of 5.9 times, I reckon it could be considered too cheap to miss at the moment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Small-Cap Shares

This 13p penny stock’s on fire! Should I buy it?

This UK penny stock has been making investors a lot of money in recent months. Is it worth buying today…

Read more »

Investing Articles

Am I missing out by not buying FTSE bank gem Standard Chartered?

Despite its recent price rise, FTSE 100 bank Standard Chartered still looks very undervalued against its peers and appears set…

Read more »

Mature black couple enjoying shopping together in UK high street
Investing Articles

£10k to invest in an ISA? Here’s how I’d use it to aim for a £97k annual passive income

Harvey Jones reckons he can build a high and rising passive income by investing in a spread of high-yielding FTSE…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

Dividend giant Legal & General’s share price still looks cheap, so should I buy more?

Legal & General’s share price still looks undervalued to me, with the company set for strong growth and continuing to…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

Up 32% this month! Is it finally time to buy this falling FTSE 250 stock?

After years of consistent losses that have slashed the share price in half, this troubled FTSE 250 stock’s making sudden…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Growth Shares

Could the Rolls-Royce share price be above 500p by the year end?

Jon Smith questions whether the Rolls-Royce share price could push higher if upcoming results look good, but balances it out…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

One dirt cheap income stock I’d buy in an ISA today and it’s not Imperial Brands or Vodafone

Harvey Jones is on the hunt for a top FTSE 100 income stock at a low price. He's ruled out…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

£20,000 in savings? Here’s how I’d try to turn it into a £2,987 monthly passive income

Investing in FTSE 100 and FTSE 250 shares can unlock a life-changing passive income over time, as Royston Wild explains.

Read more »